89bio, Inc. ETNB
Institutional shares held
108 Million
73.6K
calls
1.19M
puts
Total value of holdings
$1.05B
$712K
calls
$11.5M
puts
Market Cap
$450M
46,484,500
Shares Out.
Institutional ownership
232.99%
# of Institutions
164
We take great care to ensure that the data presented and summarized in this overview for 89bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ETNB
View all-
Janus Henderson Group PLC London, X015.2MShares$147 Million0.06% of portfolio
-
Ra Capital Management, L.P. Boston, MA14.2MShares$137 Million1.46% of portfolio
-
Suvretta Capital Management, LLC New York, NY7.99MShares$77.4 Million2.33% of portfolio
-
Rtw Investments, LP New York, NY7.38MShares$71.4 Million0.87% of portfolio
-
Black Rock Inc. New York, NY7.02MShares$67.9 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA6.81MShares$65.9 Million1.6% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.01MShares$48.5 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V83.58MShares$34.6 Million0.08% of portfolio
-
State Street Corp Boston, MA3.25MShares$31.5 Million0.0% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V83.25MShares$31.4 Million0.03% of portfolio
Latest Institutional Activity in ETNB
Top Purchases
Top Sells
About ETNB
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Insider Transactions at ETNB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 22
2025
|
Charles Mc Wherter |
BUY
Open market or private purchase
|
Direct |
10,000
+28.57%
|
$60,000
$6.71 P/Share
|
|
Jan 21
2025
|
Charles Mc Wherter |
BUY
Open market or private purchase
|
Direct |
5,000
+25.0%
|
$30,000
$6.55 P/Share
|
|
Jan 15
2025
|
Quoc Le Nguyen |
SELL
Open market or private sale
|
Direct |
10,963
-3.88%
|
$65,778
$6.49 P/Share
|
|
Dec 12
2024
|
Harry H Mansbach Chief Medical Officer |
SELL
Grant, award, or other acquisition
|
Direct |
95,000
-27.77%
|
-
|
|
Dec 12
2024
|
Ryan Martins Chief Financial Officer |
SELL
Grant, award, or other acquisition
|
Direct |
95,000
-32.47%
|
-
|
|
Dec 12
2024
|
Quoc Le Nguyen |
SELL
Grant, award, or other acquisition
|
Direct |
95,000
-25.15%
|
-
|
|
Dec 06
2024
|
Rohan Palekar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.05%
|
$35,000
$7.89 P/Share
|
|
Dec 05
2024
|
Charles Mc Wherter |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$80,000
$8.0 P/Share
|
|
Nov 22
2024
|
Rohan Palekar Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+2.1%
|
$80,000
$8.35 P/Share
|
|
Oct 30
2024
|
Quoc Le Nguyen |
SELL
Open market or private sale
|
Direct |
27,955
-12.96%
|
$223,640
$8.12 P/Share
|
|
Sep 09
2024
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
5,352
-2.42%
|
$42,816
$8.46 P/Share
|
|
Sep 09
2024
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,212
-3.04%
|
$25,696
$8.46 P/Share
|
|
Sep 09
2024
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,352
-3.4%
|
$42,816
$8.46 P/Share
|
|
Aug 17
2024
|
Harry H Mansbach Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,046
-0.66%
|
$8,368
$8.04 P/Share
|
|
Aug 17
2024
|
Quoc Le Nguyen |
SELL
Payment of exercise price or tax liability
|
Direct |
1,046
-0.47%
|
$8,368
$8.04 P/Share
|
|
Aug 17
2024
|
Ryan Martins Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
777
-0.73%
|
$6,216
$8.04 P/Share
|
|
Aug 17
2024
|
Rohan Palekar Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,601
-1.0%
|
$36,808
$8.04 P/Share
|
|
Aug 05
2024
|
Francis Willard Sarena Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Apr 11
2024
|
Ra Capital Management, L.P. |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,408,450
+9.24%
|
$7,042,250
$5.33 P/Share
|
|
Apr 01
2024
|
Rohan Palekar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
52,718
-10.3%
|
$527,180
$10.91 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.85M
Shares
From
6
Insiders
| Open market or private purchase | 1.39M shares |
|---|---|
| Exercise of in-the-money or at-the-money derivatives securities | 1.41M shares |
| Exercise of conversion of derivative security | 25K shares |
| Grant, award, or other acquisition | 25K shares |
Sell / Disposition
442K
Shares
From
9
Insiders
| Payment of exercise price or tax liability | 60.6K shares |
|---|---|
| Open market or private sale | 96.1K shares |
| Grant, award, or other acquisition | 285K shares |